Dr Kuber Jagdale has been appointed as Chief Technology Officer and Executive Director at Cohance Lifesciences. In his new role, Kuber will implement the company’s ‘One Cohance’ operating philosophy, emphasizing standardization, collaboration, and operational excellence across its manufacturing network.
He brings nearly four decades of pharmaceutical industry experience at Cohance Lifesciences. Previously, Kuber worked at Emcure Pharmaceuticals Limited for 4 years as President, where he led the API Business unit P&L and oversaw operations, quality, SCM, portfolio management, strategy, and business development.
Before that, he served as Chief Operating Officer at Sekhmet Pharmaventures. Earlier in his career, Kuber spent 32 years at Cipla. He started as Production Manager in 1989 and later progressed to Senior Vice President of Technical Operations.
He began his career with Epic Pvt Ltd as a Production Officer. Kuber holds a BSc (Tech) in Applied Drugs, a Workshop in Flow Chemistry and Chemical Engineering, and a PhD in Pharmaceutical Science from Kennedy University of Baptist.
Read More: Joel Neoh Appointed as Managing Director at Roblox
Cohance Lifesciences is not just a brand—it’s a culmination of vision, scientific ambition, and purposeful integration. Our story began with a series of intentional moves, starting with the acquisition of RA Chem Pharma.
Over time, a deliberate series of mergers and acquisitions—including ZCL Chemicals, Avra Laboratories, Suven Pharmaceuticals, Sapala Organics, and NJ Bio—brought together differentiated capabilities in Pharma CDMO, APIs, Speciality Chemicals, Formulations, and next-gen platforms like ADCs and Oligonucleotides.
